Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
Top Page
Arcutis Biotherapeutics
(NASDAQ:ARQT)
Select Model
Select Model
Rating:63Neutral
Price Target:
$23.50
▲(5.81% Upside)
Action:ReiteratedDate:02/26/26
The score is driven primarily by strong financial progress (rapid revenue scaling, high gross margins, improved balance sheet) and a constructive earnings call (raised 2026 guidance and improving cash flow trends). Offsetting factors are still-weak cash flow consistency, loss-making valuation (negative P/E), and only neutral technical momentum.
Positive Factors
Rapid Revenue Scaling
A 123% YoY revenue increase and doubling of prescription volume indicate durable commercial adoption of ZORYVE across indications. Sustained prescription momentum supports recurring revenue, improves operating leverage as fixed costs are absorbed, and strengthens the path to sustained profitability.
High Gross Margins
Consistently ~90% gross margins indicate strong incremental profitability per prescription. High structural gross margins allow new revenue to convert to cash and reinvestment rapidly, supporting commercialization and R&D spend without materially diluting unit economics as the business scales.
Improved Balance Sheet / Lower Leverage
Material reduction in leverage and equity growth provide financial flexibility to fund commercialization and pipeline programs. Lower debt and a stronger equity base reduce refinancing and interest-rate risks, increasing resilience while management executes multi-year growth investments.
Negative Factors
Inconsistent Cash Generation
Full-year negative operating and free cash flow despite a cash-positive Q4 shows cash generation isn't yet consistently self-sustaining. Continued commercial and pipeline investment could require external financing or draw on facilities if positive cash flow isn’t maintained across quarters.
Limited Medicare Part D Access
Structural limited Part D coverage and non-preferred tier placement constrain uptake among older patients, reduce realized pricing and adherence, and limit near-term addressable market monetization. Broader Medicare penetration is expected to lag, delaying full revenue potential within this cohort.
High Commercial Investment & Execution Risk
Significant SG&A increases and planned salesforce/primary care expansion heighten execution risk: these investments must convert to sustained prescription growth. If uptake lags, operating leverage will deteriorate, prolonging losses and pressuring cash runway during multi-quarter commercialization scaling.
Arcutis Biotherapeutics (ARQT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.75B
Dividend YieldN/A
Average Volume (3M)1.30M
Price to Earnings (P/E)―
Beta (1Y)0.82
Revenue Growth129.21%
EPS Growth80.35%
CountryUS
Employees342
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.13
Shares Outstanding124,033,380
10 Day Avg. Volume1,175,657
30 Day Avg. Volume1,298,337
Financial Highlights & Ratios
PEG Ratio2.58
Price to Book (P/B)19.50
Price to Sales (P/S)9.82
P/FCF Ratio-585.47
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue7.23
Enterprise Value/Gross Profit8.01
Enterprise Value/Ebitda1.03K
Forecast
1Y Price Target
$34.33Price Target Upside54.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)0.34
Revenue Forecast (FY)$495.76M
Arcutis Biotherapeutics Business Overview & Revenue Model
Company DescriptionArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
How the Company Makes MoneyArcutis primarily makes money by selling its prescription dermatology products in the United States, with net product revenues driven by demand for ZORYVE (roflumilast) topical formulations across its approved indications. Revenue is generated through commercial distribution to wholesalers/specialty pharmacies and ultimately to patients, with reported net sales reflecting typical industry deductions such as rebates, chargebacks, returns, patient assistance programs, and distribution-related fees. The company may also generate revenue from collaboration or licensing arrangements (for example, out-licensing rights in certain territories or partnering for development/commercialization), but if such arrangements exist their financial contribution and specific terms are not available here and should be considered null.
Arcutis Biotherapeutics Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Positive
The call conveyed a largely positive operational and commercial picture: very strong top-line growth (123% YoY for FY2025), record Q4 results, robust prescription momentum, expanded approvals and encouraging pediatric Phase II data, improved profitability and positive cash flow, and raised 2026 guidance. Offsetting risks include higher SG&A/R&D investment leading to elevated operating expenses, quarter-to-quarter seasonal and gross-to-net variability (notably a Q1 headwind), limited Medicare Part D coverage with non-preferred tier placement, and execution/timing risk as the company scales its sales force and primary care efforts. Overall, the company appears to be scaling successfully while mindful of near-term investment-driven expense and access nuances.Q4-2025 Updates
Positive Updates
Strong Revenue Growth (Full Year)
Net product revenues for full year 2025 were $372.1 million, a 123% increase versus 2024, driven primarily by ZORYVE demand across indications.
Record Fourth Quarter Performance
Q4 2025 net product revenues were $127.5 million, up 84% year-over-year and 29% sequentially from Q3 2025; sequential growth driven by a 19% increase in prescription volume in the quarter.
Prescription Momentum and Market Share
Total prescription volume roughly doubled year-over-year in 2025; weekly prescriptions (4-week rolling average) reached ~22,000 scripts. ZORYVE holds ~45% share of branded nonsteroidal topical prescription volume.
Regulatory and Label Expansion Progress
FDA approvals in 2025 included ZORYVE foam 0.3% for scalp and body psoriasis (12+) and ZORYVE cream 0.05% for atopic dermatitis in children 2–5. sNDA submitted for ZORYVE cream 0.3% in psoriasis ages 2–5 with a PDUFA date of June 29, 2026.
Positive Pediatric Phase II Results (INTEGUMENT-INFANT)
Phase II infants (3–24 months) topline: 58% achieved EASI-75 at week 4 and ~33% reached EASI-75 by week 2. No treatment-emergent serious adverse events and only one discontinuation; plan to submit sNDA in Q2 2026.
Pipeline Expansion and New Programs
Initiated Phase II proof-of-concept studies for ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa (HS); IND submitted for ARQ-234 (novel biologic) with Phase I dosing expected soon.
Improved Profitability and Cash Flow
Company achieved positive cash flow from operations in Q4 2025 of $26.2 million and reported cash and marketable securities of $221.3 million as of Dec 31, 2025. Net loss for 2025 narrowed to $16.1 million vs. $140.0 million in 2024; Q4 net income was $17.4 million.
Commercial and Access Wins
Expanded commercial footprint (dermatology sales force +20% to ~160 reps) and built an initial primary care/pediatrics pilot (~30 reps). Access: >80% commercial formularies, >50% Medicaid with single-step edits, and ~1/3 of Medicare Part D plans covering ZORYVE (only branded nonsteroidal topical on some Medicare formularies).
Raised 2026 Revenue Guidance
Full year 2026 net product revenue guidance increased from $455–470 million to $480–495 million based on Q4 momentum and planned investments.
Negative Updates
Higher Operating Expenses
SG&A increased to $79.0 million in Q4 2025 (37% increase YoY) and to $274.6 million for full year 2025 (20% increase YoY) due to commercialization investments; R&D expected to increase in 2026 as pipeline programs advance.
Gross-to-Net and Seasonality Headwinds
Gross-to-net remains in the 50s; management expects a typical Q1 increase to the high 50s driven by deductible resets and higher co-pay usage, and a more pronounced Q4-to-Q1 step down in revenue seasonality in early 2026. A small channel inventory build (~2% or $2.5M) in Q4 is expected to unwind in Q1.
Medicare Part D Coverage Limited and Non-Preferred Tier
Only ~1/3 of Medicare Part D plans currently provide coverage for ZORYVE and it has been placed in non-preferred (higher cost-sharing) tiers, which may temper uptake among Medicare beneficiaries; company expects remaining Part D penetration may not occur until 2027.
Revenue Mix / Other Revenue Decline
Other revenue fell to $4.0 million in 2025 from $30.0 million in 2024 (2024 included a $25.0 million upfront license payment), reducing non-product revenue contributions YoY.
Leverage and Optional Debt Facility
Total debt stands at $108 million, with an option to draw an additional $100 million through mid-2026 — provides flexibility but indicates available leverage.
Timing and Execution Risk for Commercial Expansions
Dermatology sales force expansion and primary care/pediatric in-house build are expected to be accretive but their impact will materialize primarily in the second half of 2026; near-term quarters may see increased spend without immediate sizable revenue contribution.
Company Guidance
Arcutis raised its 2026 net product revenue guidance to $480–$495 million (up $25M at both ends from the prior $455–$470M range) driven by strong Q4 momentum (Q4 net product revenues $127.5M, +84% YoY, +29% sequential; FY2025 net product revenues $372.1M, +123% YoY; rolling 4‑week weekly scripts ≈22,000) and reaffirmed it will be cash‑flow positive on a quarterly basis through 2026; management expects gross‑to‑net to remain in the 50s (peaking in the high‑50s in Q1 due to deductible resets and a ~$2.5M/≈2% channel inventory unwind), noted ~45% share of branded nonsteroidal topical Rx volume for ZORYVE, ~1/3 Medicare Part D coverage, >80% commercial access and >50% Medicaid access, and said it will invest in a ~20% dermatology sales‑force expansion to ~160 reps plus a ~30‑rep primary care/pediatric pilot (impact expected in H2 2026), while ending 2025 with $221.3M cash & marketable securities, $26.2M positive operating cash flow in Q4, $108M total debt and an optional $100M facility through mid‑2026.Arcutis Biotherapeutics Financial Statement Overview
Summary
Strong commercial ramp and very high gross margins (~90%), with losses narrowing significantly by 2025 and improved leverage (low debt-to-equity). However, profitability and cash generation are not yet consistently positive, with 2025 operating and free cash flow still negative.Income Statement
Revenue has scaled rapidly over time (from near-zero in 2020–2021 to $376.1M in 2025) with strong recent growth (+18.3% in 2025) and very high gross profitability (gross margin ~90% in both 2024 and 2025). The key weakness is that the company is still not consistently profitable: while losses narrowed dramatically (net margin improved from -71% in 2024 to about -4% in 2025), net income remains negative in 2025 and operating profitability is still slightly below breakeven.62
Positive
Balance Sheet
Leverage has improved materially: total debt fell to $6.3M in 2025 and debt-to-equity dropped to ~0.03, down sharply from elevated levels in 2023 (~2.32). Equity has also grown to $189.5M (vs. $157.5M in 2024), supporting balance sheet resilience. The main concern is ongoing losses, reflected in negative returns on equity (still negative in 2025), which can pressure equity over time if profitability doesn’t turn sustainably positive.78
Positive
Cash Flow
Cash generation remains a weak spot: operating cash flow and free cash flow were negative in 2025 (about -$5.6M and -$6.3M), and free cash flow deteriorated sharply versus 2024 (growth -83.5%). A positive is that cash burn has improved dramatically compared with 2022–2024 when operating cash flow was deeply negative, indicating better operating leverage as revenue scales; however, the business has not yet consistently self-funded operations.45
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 376.07M | 196.54M | 59.61M | 3.69M | 0.00 |
| Gross Profit | 339.38M | 177.41M | 54.62M | 2.93M | -763.00K |
| EBITDA | 2.48M | -109.63M | -227.43M | -294.55M | -205.59M |
| Net Income | -16.14M | -140.04M | -262.14M | -311.46M | -206.36M |
Balance Sheet | |||||
| Total Assets | 432.97M | 348.89M | 341.37M | 449.27M | 408.15M |
| Cash, Cash Equivalents and Short-Term Investments | 220.98M | 227.96M | 271.86M | 409.59M | 388.60M |
| Total Debt | 6.27M | 110.58M | 205.92M | 202.54M | 77.56M |
| Total Liabilities | 243.49M | 191.35M | 252.70M | 239.69M | 110.47M |
| Stockholders Equity | 189.48M | 157.54M | 88.67M | 209.58M | 297.68M |
Cash Flow | |||||
| Free Cash Flow | -6.31M | -112.30M | -247.49M | -281.00M | -175.62M |
| Operating Cash Flow | -5.63M | -112.16M | -247.06M | -257.71M | -174.63M |
| Investing Cash Flow | -30.25M | 28.82M | 180.23M | -87.20M | -75.95M |
| Financing Cash Flow | 6.97M | 66.20M | 101.32M | 301.80M | 281.95M |
Arcutis Biotherapeutics Technical Analysis
Negative
22.21
Price Trends
25.67
Negative
26.71
Negative
21.49
Positive
Market Momentum
-1.07
Positive
35.79
Neutral
13.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARQT, the sentiment is Negative. The current price of 22.21 is below the 20-day moving average (MA) of 24.41, below the 50-day MA of 25.67, and above the 200-day MA of 21.49, indicating a neutral trend. The MACD of -1.07 indicates Positive momentum. The RSI at 35.79 is Neutral, neither overbought nor oversold. The STOCH value of 13.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARQT.
Arcutis Biotherapeutics Risk Analysis
Arcutis Biotherapeutics disclosed 72 risk factors in its most recent earnings report. Arcutis Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Arcutis Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $1.60B | 13.56 | 19.84% | ― | 21.13% | 50.86% | |
63 Neutral | $2.75B | -228.91 | -10.26% | ― | 129.21% | 80.35% | |
62 Neutral | $2.75B | ― | -19.63% | ― | 182.44% | 47.21% | |
53 Neutral | $1.72B | -2.84 | -63.98% | ― | -32.98% | -18.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $2.48B | -67.82 | -79.16% | ― | 114.22% | 77.02% | |
43 Neutral | $2.22B | -13.21 | -32.80% | ― | ― | -34.96% |
* Healthcare Sector Average
ARQT
Arcutis Biotherapeutics
22.21
4.92
28.46%
TVTX
Travere Therapeutics
26.84
5.55
26.07%
IRON
Disc Medicine
58.17
4.47
8.32%
HRMY
Harmony Biosciences Holdings
27.72
-6.52
-19.04%
TARS
Tarsus Pharmaceuticals
64.51
12.15
23.20%
RXRX
Recursion Pharmaceuticals
3.25
-3.54
-52.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.